Results 11 to 20 of about 5,551,009 (351)

Cancer immunotherapy

Current Opinion in Immunology, 2013
The war on cancer began a little more than 40 years ago as a national research program to radically improve the survival of patients with cancer, a leading cause of death in the United States and worldwide. The main weapons deployed have been surgery, radiation, and chemotherapy, treatments that often carry risks and/or cause adverse side effects ...
Thomas F, Gajewski, Ton, Schumacher
  +8 more sources

Delivery technologies for cancer immunotherapy

Nature Reviews Drug Discovery, 2019
Rachel S. Riley, C. June, R. Langer, M. J. Mitchell   +3 more
semanticscholar   +3 more sources

Immunotherapy & thoracic cancers [PDF]

Journal of Thoracic Disease, 2018
Thoracic malignancies present a significant global health burden with the incidence and mortality of both lung cancer and malignant pleural mesothelioma (MPM) increasing by year. Lung cancer, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), is the leading cause of cancer-related deaths, worldwide.
Silvia Novello, Antonio Rossi
openaire   +3 more sources

Immunotherapy of lung cancer: An update [PDF]

, 2006
In Germany lung cancer is the leading cause of cancer-associated death in men. Surgery, chemotherapy and radiation may enhance survival of patients suffering from lung cancer but the enhancement is typically transient and mostly absent with advanced ...
Aman MJ, Anthony HM, Atanackovic D, Bast RC, Bermers AJA, Carbone FR, Chan B, Cohen MH, Dickler M, Dranoff G, Dudley ME, Faradji A, Gotoh K, Grant SC, Kimura H, Kimura Y, Korkolopoulou P, Kradin RL, Krug LM, Krug LM, Liu M, Ma J, Marshall JL, Melioli G, Millar JW, Nemunaitis J, Nikitina E, O'Brien ME, Palmer M, Raez LE, Ratto GB, Salgia R, Smith A, Sterman D, Swisher S, Villalona-Calero MA, Yano T   +36 more
core   +1 more source

Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1

Journal for ImmunoTherapy of Cancer, 2019
Background Several predictive biomarkers are currently approved or are under investigation for the selection of patients for checkpoint blockade. Tumor PD-L1 expression is used for stratification of non-small cell lung (NSCLC) patients, with tumor ...
Kellie N. Smith, Nicolas J. Llosa, Tricia R. Cottrell, Nicholas Siegel, Hongni Fan, Prerna Suri, Hok Yee Chan, Haidan Guo, Teniola Oke, Anas H. Awan, Franco Verde, Ludmila Danilova, Valsamo Anagnostou, Ada J. Tam, Brandon S. Luber, Bjarne R. Bartlett, Laveet K. Aulakh, John-William Sidhom, Qingfeng Zhu, Cynthia L. Sears, Leslie Cope, William H. Sharfman, Elizabeth D. Thompson, Joanne Riemer, Kristen A. Marrone, Jarushka Naidoo, Victor E. Velculescu, Patrick M. Forde, Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Jennifer N. Durham, Hao Wang, Dung T. Le, Sune Justesen, Janis M. Taube, Luis A. Diaz, Julie R. Brahmer, Drew M. Pardoll, Robert A. Anders, Franck Housseau   +40 more
doaj   +1 more source

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. [PDF]

, 2016
Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer death among men in the United States. In recent years, several new agents, including cancer immunotherapies, have been approved or are currently being ...
Bander, Neil H, Beer, Tomasz M, Drake, Charles G, Fong, Lawrence, Gulley, James L, Harrelson, Stacey, Kantoff, Philip W, Madan, Ravi A, McNeel, Douglas G, Oh, William K, Peace, David J, Petrylak, Daniel P, Porterfield, Hank, Sartor, Oliver, Shore, Neal D, Slovin, Susan F, Stein, Mark N, Vieweg, Johannes   +17 more
core   +1 more source

High Complete Response Rate in Patients With Metastatic Renal Cell Carcinoma Receiving Autologous Cytokine-Induced Killer Cell Therapy Plus Anti-Programmed Death-1 Agent: A Single-Center Study

Frontiers in Immunology, 2022
Background and ObjectiveThe results of the CheckMate 025 trial established the status of nivolumab in the second-line treatment of metastatic renal cell carcinoma (mRCC), with an objective response rate (ORR) of 25% and a complete response (CR) rate of 1%
Lingdi Zhao, Tiepeng Li, Yongping Song, Yonghao Yang, Baozhen Ma, Yong Zhang, Yiman Shang, Benling Xu, Jindong Guo, Peng Qin, Lu Han, Xiaomin Fu, Hongwei Lin, Liang Liu, Xiubao Ren, Zibing Wang, Quanli Gao   +16 more
doaj   +1 more source

Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again

Genome Medicine, 2018
For at least 300 years the immune system has been targeted to improve human health. Decades of work advancing immunotherapies against infection and autoimmunity paved the way for the current explosion in cancer immunotherapies.
Samantha L. Bucktrout, Jeffrey A. Bluestone, Fred Ramsdell   +2 more
doaj   +1 more source

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. [PDF]

, 2017
Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a discrete group of immune-related adverse ...
Abdallah, K., Anderson, J., Andrews, S., Arrindell, D., Ballesteros, J., Bingham, C. O., Boyer, J., Brogdon, C., Chen, D., Chonzi, D., Cotarla, I., Cunha, R., Dadu, R., Davies, M., Dawson, M., Diab, A., Dicker, Adam, Eifler, L., Ernstoff, M. S., Ferguson, A., Ferlini, C., Frankel, S., Go, W., Gochett, C., Goldberg, J., Goncalves, P., Goswami, T., Gregory, N., Gulley, J. L., Hamad, L., Hayreh, V., Helie, N., Holmes, W., Hsu, J. Y., Ibrahim, R., Kaufman, H. L., Kim, S., Lacouture, M. E., Lambotte, O., Larocca, C., LeBoeuf, N. R., Lehman, K., Lenihan, D., Ley-Acosta, S., Luke, J., McClure, J., Michelon, E., Nakamura, M., Onofrei, C., Patel, K., Piperdi, B., Puzanov, I., Rasheed, Z., Reshef, D., Riemer, J., Robert, C., Sarkeshik, M., Saylors, A., Schreiber, J., Shafer-Weaver, K., Shannon, V., Sharfman, W., Sharma, R., Sharon, E., Sherry, R., Silk, A. W., Simonson, C., Skondra, D., Suarez-Almazor, M. E., Thomas, C., Thompson, J. A., Trehu, E., Tresnan, D., Turner, M., Wang, Y., Wariabharaj, D., Waxman, I., Wiley, K., Wood, L., Zhang, L., Zheng, P.   +80 more
core   +2 more sources

Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy

Nature reviews. Immunology, 2021
A paradigm shift has recently occurred in the field of cancer therapeutics. Traditional anticancer agents, such as chemotherapy, radiotherapy and small-molecule drugs targeting specific signalling pathways, have been joined by cellular immunotherapies ...
E. Morris, S. Neelapu, Theodoros Giavridis, M. Sadelain   +3 more
semanticscholar   +1 more source